Insulet (NASDAQ:PODD) Sets New 52-Week Low – Here’s What Happened

Shares of Insulet Corporation (NASDAQ:PODD) reached a new 52-week low during mid-day trading on Wednesday . The stock traded as low as $141.02 and last traded at $143.4140, with a volume of 177186 shares. The stock had previously closed at $153.80.

Analyst Ratings Changes

Several research firms have recently commented on PODD. Stifel Nicolaus reduced their target price on Insulet from $350.00 to $250.00 in a research note on Thursday, May 7th. BTIG Research dropped their price target on shares of Insulet from $260.00 to $235.00 and set a “buy” rating for the company in a research note on Tuesday. Evercore cut their price target on shares of Insulet from $240.00 to $200.00 in a report on Thursday, May 7th. Weiss Ratings downgraded shares of Insulet from a “hold (c)” rating to a “hold (c-)” rating in a research note on Friday, May 15th. Finally, Royal Bank Of Canada reissued an “outperform” rating and set a $280.00 price objective on shares of Insulet in a report on Wednesday. Twenty-one investment analysts have rated the stock with a Buy rating, five have issued a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $252.48.

Insulet Trading Down 5.5%

The company has a market cap of $10.06 billion, a price-to-earnings ratio of 33.86, a price-to-earnings-growth ratio of 1.23 and a beta of 1.20. The firm has a 50-day moving average price of $188.59 and a 200 day moving average price of $248.51. The company has a current ratio of 2.49, a quick ratio of 1.81 and a debt-to-equity ratio of 0.71.

Insulet (NASDAQ:PODD) last posted its quarterly earnings results on Wednesday, May 6th. The medical instruments supplier reported $1.42 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.19 by $0.23. Insulet had a return on equity of 26.87% and a net margin of 10.44%.The business had revenue of $761.70 million for the quarter, compared to analyst estimates of $729.89 million. During the same period in the prior year, the company posted $1.02 EPS. The business’s revenue was up 33.9% compared to the same quarter last year. Insulet has set its FY 2026 guidance at 6.210- EPS. As a group, sell-side analysts forecast that Insulet Corporation will post 6.43 EPS for the current year.

Institutional Investors Weigh In On Insulet

A number of institutional investors have recently modified their holdings of the business. Larson Financial Group LLC raised its stake in Insulet by 114.6% during the fourth quarter. Larson Financial Group LLC now owns 88 shares of the medical instruments supplier’s stock worth $25,000 after acquiring an additional 47 shares during the period. University of Texas Texas AM Investment Management Co. acquired a new position in Insulet in the fourth quarter valued at approximately $26,000. Elyxium Wealth LLC acquired a new position in Insulet in the fourth quarter valued at approximately $28,000. DV Equities LLC bought a new position in shares of Insulet during the fourth quarter valued at approximately $28,000. Finally, MV Capital Management Inc. acquired a new stake in shares of Insulet during the 4th quarter worth approximately $29,000.

Insulet Company Profile

Insulet Corporation is a medical device company headquartered in Acton, Massachusetts, that develops, manufactures and sells insulin-delivery systems for people with diabetes. The company’s core business is the design and commercialization of its Omnipod family of tubeless, wearable insulin pumps and the consumable Pods that deliver insulin. Insulet’s products aim to simplify insulin delivery for people with type 1 diabetes and insulin-requiring type 2 diabetes by offering an alternative to traditional insulin pens and tethered pump systems.

The company’s product portfolio includes the Omnipod System line—disposable, waterproof Pods that adhere to the skin and deliver insulin—and the associated controllers and mobile applications used to program and monitor insulin delivery.